Brief: Sesen Bio Currently Estimates It Will Incur Aggregate Restructuring Charges In Q3, Q4 Ranging About $13 Million To 14 Million
11/08/2022 15:12
Aug 11 (Reuters) - Sesen Bio Inc SESN.O :
* SESEN BIO - CURRENTLY ESTIMATES IT WILL INCUR AGGREGATE
RESTRUCTURING CHARGES IN Q3, Q4 2022 RANGING FROM APPROXIMATELY
$13 MILLION TO 14 MILLION
Further company coverage: SESN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary